San Diego, CA -- (SBWIRE) -- 01/23/2018 -- An investigation was announced for investors of Axovant Sciences Ltd (NASDAQ:AXON) shares over potential securities laws violations by Axovant Sciences.

Investors in shares of Axovant Sciences Ltd (NASDAQ:AXON), should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Axovant Sciences Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

London based Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company that is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. Shares of Axovant Sciences Ltd (NASDAQ:AXON) declined from $24.99 per share in September 2017 to as low as $2.03 per share on January 16, 2018.

Those who purchased shares of Axovant Sciences Ltd (NASDAQ:AXON) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com